FDA Accepts Supplement for STEGLUJAN (Ertugliflozin/Sitagliptin)
The FDA has accepted a supplemental application for STEGLUJAN, a combination of ertugliflozin and sitagliptin.
Published: July 23, 2026
Updated: July 23, 2026
Author: Humanexa Intelligence
Therapeutic area: Diabetes / SGLT2 Inhibitor / DPP-4 Inhibitor
Company: Merck
Asset: STEGLUJAN
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Merck
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's acceptance of the supplemental application for STEGLUJAN is significant as it may strengthen Merck's competitive position in the diabetes market. This development necessitates strategic planning to effectively position against rival combination therapies.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the timeline for approval and any subsequent market launch announcements.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.